Time: 9:30 am - 12:30 pm
day: Pre-Conference Workshop Day
Effectively reducing the doses of AAV vectors required to successfully treat patients could be the key to improving the overall safety of AAV gene therapies. However, this is easier said than done and there are several obstacles to overcome for this to become a reality for gene therapies. Join this deep dive session to learn about the latest advancements reducing AAV vector dosage.
Attend this workshop to:
• Understand the safety issues with high vector doses
• Explore the advancements made towards re-dosing to minimize high vector dose requirements
• Clarify the vector genomes are accurate to ensure a functional product is produced and use the minimal vector dose required